According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months...

Click here to see Dan's full warning (and his potential solution)

Gregg Alton Biography and Net Worth

EVP of Gilead Sciences

Gregg Alton is former chief patient officer at Gilead Sciences, where he led patient outreach and engagement initiatives and efforts to facilitate access to medicines around the world. Mr. Alton joined Gilead in 1999 and held positions including general counsel, chief compliance officer, and secretary. He oversaw the company’s corporate and medical affairs functions, developing world access programs and commercial operations in emerging markets. Mr. Alton also served as interim chief executive officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP. Mr. Alton is a member of the President’s Advisory Council on HIV/Aids and serves on the boards of Corcept Therapeutics, Novavax, Inc., Enochian Biosciences, the Boys and Girls Clubs of Oakland, and the Hepatitis Fund. He is a member of the board of directors of Enochiam Biosciences and Collidion, Inc.

What is Gregg H. Alton's net worth?: The estimated net worth of Gregg H. Alton is at least $6.40 million as of March 1st, 2018. Alton owns 69,426 shares of Gilead Sciences stock worth more than $6,403,854 as of November 14th. This net worth approximation does not reflect any other investments that Alton may own. Learn More about Gregg H. Alton's net worth.
How do I contact Gregg H. Alton?: The corporate mailing address for Alton and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Gregg H. Alton's contact information.
Has Gregg H. Alton been buying or selling shares of Gilead Sciences?: Gregg H. Alton has not been actively trading shares of Gilead Sciences in the last ninety days. Most recently, Gregg H. Alton sold 25,000 shares of the business's stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $78.69, for a transaction totalling $1,967,250.00. Following the completion of the sale, the executive vice president now directly owns 69,426 shares of the company's stock, valued at $5,463,131.94. Learn More on Gregg H. Alton's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 81,679 shares worth more than $6,935,730.32. The most recent insider tranaction occured on November, 6th when insider Merdad Parsey sold 25,590 shares worth more than $2,341,485.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/6/2024.

Gregg H. Alton Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2018	Sell	25,000	$78.69	$1,967,250.00	69,426
2/20/2018	Sell	14,435	$81.54	$1,177,029.90
2/1/2018	Sell	25,000	$83.51	$2,087,750.00	62,738
1/11/2018	Sell	30,000	$79.00	$2,370,000.00	57,114
1/2/2018	Sell	15,000	$73.87	$1,108,050.00	64,613
12/1/2017	Sell	15,000	$74.64	$1,119,600.00	70,988
11/1/2017	Sell	15,000	$74.82	$1,122,300.00	77,363
10/2/2017	Sell	25,000	$82.65	$2,066,250.00
9/1/2017	Sell	25,000	$83.05	$2,076,250.00	101,488
8/30/2017	Sell	50,000	$79.00	$3,950,000.00	113,237
8/1/2017	Sell	15,000	$75.88	$1,138,200.00	106,113
7/21/2017	Sell	40,000	$74.00	$2,960,000.00	137,488
7/3/2017	Sell	5,000	$71.06	$355,300.00	102,988
3/30/2017	Sell	5,000	$67.48	$337,400.00	117,988
9/22/2016	Sell	5,000	$81.84	$409,200.00	132,964
4/19/2016	Sell	40,000	$100.01	$4,000,400.00	177,964
3/14/2016	Sell	5,000	$90.00	$450,000.00	147,090
11/2/2015	Sell	12,000	$109.38	$1,312,560.00	131,422
10/26/2015	Sell	5,000	$110.00	$550,000.00	133,422
10/5/2015	Sell	5,000	$100.00	$500,000.00	133,422
9/15/2015	Sell	5,000	$110.00	$550,000.00	135,422
6/1/2015	Sell	17,000	$113.64	$1,931,880.00
4/1/2015	Sell	7,000	$96.53	$675,710.00
2/2/2015	Sell	12,000	$105.73	$1,268,760.00
1/8/2015	Sell	5,000	$100.89	$504,450.00
1/2/2015	Sell	7,000	$95.17	$666,190.00
9/2/2014	Sell	33,000	$108.58	$3,583,140.00
8/1/2014	Sell	33,000	$91.62	$3,023,460.00
7/1/2014	Sell	33,000	$84.12	$2,775,960.00
6/2/2014	Sell	33,000	$81.35	$2,684,550.00
8/1/2013	Sell	30,000	$61.49	$1,844,700.00
7/1/2013	Sell	30,000	$52.09	$1,562,700.00
6/3/2013	Sell	30,000	$52.77	$1,583,100.00
12/3/2012	Sell	44,000	$75.10	$3,304,400.00
9/4/2012	Sell	44,000	$57.50	$2,530,000.00

Gregg H. Alton Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $92.24

$91.29

$92.51

50 Day Range

MA: $86.22

$78.72

$97.90

2 Week Range

Now: $92.24

$62.07

$98.90

Volume

4,199,160 shs

Average Volume

7,064,631 shs

Market Capitalization

$114.84 billion

P/E Ratio

1,024.89

Dividend Yield

3.17%

Beta

0.17

Post-Election Bitcoin Warning

From Stansberry Research | Ad